Reckitt Benckiser is considering options for its infant nutrition business, including a potential sale, Bloomberg News has reported, citing people familiar with the matter.
The British consumer goods giant, whose brands include Enfamil formula, is reviewing its baby-food business globally and has been informally weighing buyer interest in the operations, the report said.
The deliberations are at an early stage and the London-listed firm could decide to keep the division, according to the report.
Reckitt did not immediately respond to a Reuters request for comment.
Reuters had reported in 2020 that the company was preparing to sell some non-core brands and was seeking out private equity bidders.
Last year, Reckitt sold its baby formula business in China to investment firm Primavera Capital Group.
In December, the company announced plans to sell its E45 skincare brand and related sub-brands to Karo Pharma for £200 million (€236.4 million) to focus on higher growth areas.
The Slough-based company has been trimming its portfolio to concentrate on high growth categories such as disinfectants and health care products that have seen a boom during the COVID-19 pandemic.
The home and personal care firm raised its full-year forecast after reporting higher-than-expected third-quarter sales in October 2021, driven by price hikes and growth in demand for several of its products.
The group reported 3.3% rise in like-for-like sales for the third quarter, beating the 0.7% decline analysts had expected, according to a company-supplied consensus.